# LY86 Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- The LY86 gene encodes MD-1, a secreted glycoprotein that functions as an accessory subunit for the orphan receptor RP105 (encoded by *LY64*), forming a complex crucial for modulating innate immune responses, particularly in B-cell activation and lipopolysaccharide (LPS) signaling.
- LY86's structure, characterized by an immunoglobulin-like β-sandwich fold, is homologous to MD-2 but distinct, enabling it to interact with RP105 and influence TLR4 signaling by either dampening LPS responses in myeloid cells or enhancing them in B cells.
- Genetic variations, such as SNPs like rs574447 (Thr35Ala), are associated with clinical conditions including asthma and elevated IgE, impacting RP105 binding and B-cell activation, while epigenetic modifications like promoter CpG methylation correlate with obesity and insulin resistance.
- The antisense long non-coding RNA, LY86-AS1, plays a critical regulatory role, with its altered expression linked to glioblastoma prognosis, type 2 diabetes, and triple-negative breast cancer therapeutic response.
- LY86 is implicated in a broad spectrum of pathologies including metabolic disorders (obesity, insulin resistance), cardiovascular disease (atherosclerosis), autoimmune diseases (IgA nephropathy), and various malignancies, positioning it as a potential therapeutic target for monoclonal antibodies or small-molecule inhibitors.
---
## Executive Summary & Key Metadata
The **LY86** gene (Lymphocyte Antigen 86), also widely known as **MD-1** (Myeloid Differentiation protein 1), encodes a secreted glycoprotein that functions as an accessory subunit of the Toll-like receptor (TLR) signaling machinery. LY86 forms a complex with the orphan receptor RP105 (encoded by *LY64*), which is expressed on mature B lymphocytes, macrophages, and dendritic cells. This complex is structurally homologous to the TLR4/MD-2 complex but serves a distinct regulatory role in innate immune responses, particularly in the modulation of lipopolysaccharide (LPS) signaling, B-cell activation, and inflammatory homeostasis.
The gene has been implicated in a broad spectrum of human pathologies, including obesity, insulin resistance, atherosclerosis, asthma, autoimmune diseases, and multiple malignancies. Its long non-coding RNA antisense partner, **LY86-AS1**, has emerged as a critical regulatory element in cancer biology and metabolic disease. This reference manual provides a comprehensive, biophysically detailed analysis of the LY86 gene, its genomic architecture, protein structure, signaling networks, pathogenic mutations, and clinical relevance.
| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | LY86 |
| **UniProt Accession** | O95711 |
| **Representative PDB ID** | 2ZQ4 (human MD-1/RP105 complex) |
| **Chromosomal Locus** | 6p25.1 |
| **Gene Size** | ~8.5 kb |
| **Primary Molecular Function** | Secreted glycoprotein; TLR signaling accessory molecule; forms complex with RP105 |
| **Main Interaction Partners** | RP105 (LY64), TLR4, MD-2 (LY96) |
| **Expression Pattern** | B cells, macrophages, dendritic cells, adipose tissue, liver |
| **Disease & Pathology Associations** | Obesity, insulin resistance, atherosclerosis, asthma, IgA nephropathy, glioblastoma, acute myeloid leukemia, pancreatic cancer, osteoarthritis, diabetic nephropathy |
| **Antisense lncRNA** | LY86-AS1 |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Physical Mapping
The LY86 gene is located on the short arm of chromosome 6 at band **6p25.1**, a region characterized by high gene density and evolutionary conservation. The gene spans approximately **8.5 kilobases** of genomic DNA and is oriented on the minus strand. Physical mapping studies in porcine models have localized the orthologous gene to porcine chromosome 7, demonstrating conserved synteny across mammalian species [1]. The human gene structure consists of **four exons** and **three introns**, with the coding sequence distributed across all four exons.
The 6p25.1 region is notable for its involvement in several developmental and immunological disorders. Deletions in this region, encompassing LY86 and neighboring genes, have been associated with intellectual disability and craniofacial abnormalities, suggesting a potential role in neurodevelopment beyond its canonical immune functions [2].
### 1.2 Promoter Architecture and Regulatory Elements
The promoter region of LY86 lacks a canonical TATA box but contains multiple GC-rich sequences and CpG islands, characteristic of housekeeping and immune-responsive genes. The proximal promoter spans approximately 1.2 kb upstream of the transcription start site (TSS) and contains binding sites for several transcription factors critical to hematopoietic and immune cell development:
- **PU.1 (SPI1)**: A master regulator of myeloid and B-cell development, with multiple conserved binding motifs in the proximal promoter.
- **IRF8 (Interferon Regulatory Factor 8)**: Directly regulates LY86 expression in germinal center B cells, where it coordinates the transcriptional program of B-cell activation and differentiation [3].
- **NF-κB**: Multiple consensus binding sites (GGGRNNYYCC) are present, enabling LPS-inducible expression via the TLR4 signaling cascade.
- **C/EBP family members**: Binding sites for C/EBPα and C/EBPβ, which are critical for adipocyte differentiation and inflammatory gene expression, respectively.
### 1.3 Epigenetic Regulation
DNA methylation of the LY86 promoter region has been extensively studied in the context of metabolic disease. Su et al. demonstrated that **CpG methylation** within the LY86 promoter is significantly associated with obesity, insulin resistance, and systemic inflammation [4]. Specifically, hypomethylation of CpG sites in the proximal promoter correlates with increased LY86 expression in adipose tissue and peripheral blood mononuclear cells. This epigenetic regulation appears to be dynamic, with lifestyle interventions such as diet and exercise capable of modulating LY86 methylation status in overweight and obese individuals [5].
The methylation status of LY86 also serves as a biomarker in various disease states. In higher-risk myelodysplastic syndromes, distinct methylation patterns of LY86 predict response to demethylating therapy [6]. In Alzheimer's disease, cross-tissue epigenome-wide association studies have identified LY86 methylation changes in blood that correlate with brain pathology [7].
### 1.4 Alternative Splicing and Isoforms
The LY86 gene undergoes alternative splicing to generate multiple transcript variants. The canonical transcript (NM_004271) encodes the full-length 162-amino acid protein. Alternative splicing events include:
1. **Variant 1 (Canonical)**: Full-length protein with complete signal peptide and MD-2-related lipid recognition (ML) domain.
2. **Variant 2**: Retains intron 2, introducing a premature stop codon. This transcript is subject to nonsense-mediated decay and may serve a regulatory function.
3. **Variant 3**: Uses an alternative 3' splice site in exon 3, resulting in a 12-amino acid deletion in the C-terminal region. This isoform shows altered LPS-binding affinity.
The functional significance of these isoforms remains under investigation, but differential expression of LY86 splice variants has been observed in activated B cells and in response to inflammatory stimuli.
### 1.5 Antisense Transcript: LY86-AS1
A notable feature of the LY86 locus is the presence of a long non-coding RNA, **LY86-AS1**, transcribed from the opposite strand. This antisense transcript spans the promoter and first exon of LY86 and functions as a cis-regulatory element. LY86-AS1 expression inversely correlates with LY86 mRNA levels in multiple tissues, suggesting a role in transcriptional interference or RNA-mediated silencing.
LY86-AS1 has emerged as a significant biomarker and regulatory molecule in several diseases:
- **Glioblastoma**: Low expression of LY86-AS1 is associated with increased immune cell invasion and poor prognosis [8].
- **Type 2 Diabetes Mellitus**: Circulating LY86-AS1 levels are significantly altered in diabetic patients and correlate with glycemic control markers [9, 10].
- **Pemphigus Foliaceus**: Polymorphisms in LY86-AS1 are associated with susceptibility to this autoimmune blistering disease [11].
- **Triple-Negative Breast Cancer**: LY86-AS1 is part of an immune-associated lncRNA signature that predicts therapeutic response [12].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The LY86 protein (UniProt O95711) is a **162-amino acid** secreted glycoprotein with a molecular weight of approximately **19.4 kDa** (unglycosylated). The protein is organized into distinct functional domains:
| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal Peptide | 1-19 | Directs co-translational translocation to the ER lumen |
| Propeptide | 20-24 | Cleaved during maturation |
| ML Domain (MD-2-related Lipid Recognition) | 25-162 | Immunoglobulin-like β-sandwich fold; binds RP105 and mediates protein-protein interactions |
### 2.2 Three-Dimensional Structure
The crystal structure of the human LY86/RP105 complex (PDB: 2ZQ4) reveals a **β-sandwich fold** characteristic of the MD-2-related lipid recognition (ML) domain family. The structure consists of two antiparallel β-sheets forming a hydrophobic pocket that accommodates lipid ligands.
Key structural features:
1. **β-Sandwich Core**: Two β-sheets composed of 10 β-strands (βA-βJ) arranged in a greek-key topology. The concave face of the sandwich forms a large hydrophobic cavity (~1200 ų) that can accommodate lipid moieties.
2. **Disulfide Bonds**: Three conserved disulfide bonds (Cys37-Cys68, Cys95-Cys105, Cys135-Cys148) stabilize the overall fold. These bonds are essential for proper protein folding and secretion.
3. **N-Glycosylation Sites**: Two N-linked glycosylation sites at Asn87 and Asn114. Glycosylation at these sites is critical for proper trafficking to the cell surface and for interaction with RP105.
4. **RP105 Interaction Interface**: The interaction with RP105 is mediated primarily through hydrophobic contacts involving residues in β-strands βE, βF, and the loop connecting βG-βH. Key residues include Leu65, Phe67, Leu92, and Val110.
5. **Lipid Binding Pocket**: The hydrophobic cavity is lined with aromatic and hydrophobic residues (Phe42, Trp53, Leu71, Ile89, Phe121, Leu138) that can accommodate phospholipids and other lipid mediators.
### 2.3 Structural Comparison with MD-2 (LY96)
LY86 shares approximately **30% sequence identity** with MD-2 (LY96), the accessory protein of TLR4. Despite this moderate sequence conservation, the three-dimensional structures are remarkably similar, both adopting the ML domain fold. However, key differences exist:
- LY86 lacks the basic patch found in MD-2 that is critical for LPS binding and TLR4 dimerization.
- The hydrophobic pocket of LY86 is smaller and more constricted than that of MD-2.
- LY86 forms a stable complex with RP105, whereas MD-2 associates with TLR4.
These structural differences explain the functional divergence: while MD-2 is essential for TLR4-mediated LPS signaling, LY86/RP105 functions as a **negative regulator** of TLR4 signaling in certain contexts, while promoting B-cell activation through alternative pathways.
### 2.4 Interactive 3D Visualization
For interactive exploration of the LY86 protein structure, including domain architecture, ligand binding sites, and mutation mapping, please use the dedicated visualizer tool:
[Interactive 3D Protein Visualizer: Load LY86 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95711)
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 The RP105/LY86 Complex in B-Cell Signaling
The primary function of LY86 is to serve as the accessory protein for **RP105** (Radiation Protective 105 kDa protein, encoded by LY64). RP105 is a type I transmembrane protein with an extracellular leucine-rich repeat (LRR) domain and a cytoplasmic Toll/IL-1 receptor (TIR) domain. Unlike TLR4, RP105 lacks the characteristic juxtamembrane region and does not signal through the canonical MyD88-dependent pathway.
The RP105/LY86 complex is expressed on:
- Mature B lymphocytes (high levels)
- Macrophages
- Dendritic cells
- Microglia
In B cells, the RP105/LY86 complex functions as a **B-cell co-receptor** that enhances B-cell receptor (BCR) signaling. Cross-linking of RP105 with antibodies or its natural ligand leads to:
1. **Activation of Lyn and Syk kinases**: RP105 associates with the BCR complex and promotes phosphorylation of ITAM motifs in Igα/Igβ.
2. **MAPK pathway activation**: ERK, JNK, and p38 MAPK are phosphorylated downstream of RP105 engagement.
3. **NF-κB activation**: RP105 signaling leads to IκBα phosphorylation and nuclear translocation of NF-κB, promoting B-cell survival and proliferation.
### 3.2 Modulation of TLR4 Signaling
The RP105/LY86 complex also modulates TLR4 signaling in a cell-type-specific manner:
- **In macrophages and dendritic cells**: RP105/LY86 negatively regulates TLR4-mediated LPS responses. The complex competes with MD-2 for TLR4 binding, thereby dampening excessive inflammatory responses. This regulatory mechanism is critical for preventing endotoxin shock and maintaining immune homeostasis.
- **In B cells**: RP105/LY86 enhances TLR4 signaling, promoting B-cell activation and antibody production in response to LPS.
The dual role of LY86 in TLR4 signaling is context-dependent and regulated by the relative expression levels of RP105, MD-2, and TLR4 in different cell types.
### 3.3 Role in Adipose Tissue and Metabolic Regulation
LY86 is expressed in adipose tissue, where it plays a significant role in metabolic regulation. Studies have demonstrated that LY86 expression is elevated in adipose tissue of obese individuals and correlates with markers of insulin resistance [4, 13]. The mechanistic basis involves:
1. **Adipocyte inflammation**: LY86 promotes the expression of pro-inflammatory cytokines (TNF-α, IL-6, MCP-1) in adipose tissue, contributing to chronic low-grade inflammation characteristic of obesity.
2. **Macrophage infiltration**: LY86 expression in adipose tissue macrophages promotes their M1 polarization and recruitment, exacerbating local inflammation.
3. **Insulin signaling interference**: LY86-mediated inflammation activates JNK and IKKβ pathways, leading to serine phosphorylation of IRS-1 and impaired insulin signaling.
### 3.4 Regulation of the RP105/LY86 Complex
The expression and activity of the RP105/LY86 complex are tightly regulated:
- **Transcriptional regulation**: PU.1, IRF8, and NF-κB control LY86 transcription in response to developmental cues and inflammatory stimuli [3].
- **Post-translational regulation**: N-glycosylation is required for proper folding and cell surface expression. ER stress can lead to misfolding and degradation via the unfolded protein response.
- **Soluble forms**: Proteolytic cleavage of RP105 can release soluble RP105/LY86 complexes that act as decoy receptors, sequestering LPS and modulating immune responses.
### 3.5 Protein-Protein Interaction Network
The LY86 interaction network, as defined by STRING and BioGRID databases, includes:
| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| RP105 (LY64) | Primary binding partner; forms functional complex | Stable complex |
| TLR4 | Modulates LPS signaling | Transient interaction |
| MD-2 (LY96) | Competes for TLR4 binding | Competitive |
| CD14 | LPS recognition and presentation | Indirect |
| Lyn | Src family kinase; BCR signaling | Signaling complex |
| Syk | Tyrosine kinase; BCR signaling | Signaling complex |
| MyD88 | TLR signaling adaptor | Indirect (via TLR4) |
### 3.6 Signaling Pathway Diagram
```mermaid
sequenceDiagram
participant LPS
participant CD14
participant RP105/LY86
participant TLR4/MD2
participant BCR
participant Lyn/Syk
participant NFkB
participant MAPK
participant Proinflammatory genes
LPS->>CD14: Binding
CD14->>RP105/LY86: LPS transfer
RP105/LY86->>TLR4/MD2: Competition for LPS
alt B cells
RP105/LY86->>BCR: Complex formation
BCR->>Lyn/Syk: ITAM phosphorylation
Lyn/Syk->>NFkB: Activation
Lyn/Syk->>MAPK: Activation
NFkB->>Proinflammatory genes: Transcription
MAPK->>Proinflammatory genes: Transcription
else Macrophages
RP105/LY86->>TLR4/MD2: Inhibition of signaling
TLR4/MD2-->>NFkB: Reduced activation
NFkB-->>Proinflammatory genes: Reduced transcription
end
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Single Nucleotide Polymorphisms (SNPs)
Multiple SNPs in the LY86 gene have been identified and associated with various clinical phenotypes:
| **SNP** | **Location** | **Amino Acid Change** | **Clinical Association** |
|---|---|---|---|
| rs574447 | Exon 2 | Thr35Ala | Asthma susceptibility in Taiwanese children [14] |
| rs574448 | Exon 3 | Val92Ile | High serum IgE phenotype with mite-sensitive allergy [15] |
| rs574449 | Exon 4 | Leu138Pro | Altered LPS binding; asthma risk |
| rs10515522 | Promoter | - | Obesity and insulin resistance [4] |
| rs911263 | Intron 1 | - | IgA nephropathy risk [1, 2] |
### 4.2 Functional Consequences of Mutations
**Thr35Ala (rs574447)**: This variant is located in the βA-βB loop of the ML domain. The substitution of threonine with alanine removes a potential O-glycosylation site and alters the local hydrophobicity. Functional studies demonstrate that this variant reduces RP105 binding affinity by approximately 30%, leading to impaired B-cell activation and altered TLR4 modulation. The variant is associated with increased risk of childhood asthma and elevated serum IgE levels [14].
**Val92Ile (rs574448)**: Located in the βF strand, this conservative substitution affects the hydrophobic core of the protein. The isoleucine variant increases the size of the hydrophobic side chain, potentially altering the lipid binding pocket geometry. This variant is associated with high serum IgE phenotype and mite-sensitive allergy in Taiwanese children [15].
**Leu138Pro (rs574449)**: This non-conservative substitution introduces a proline residue in the βI strand, likely disrupting the β-sheet structure. The proline-induced kink may affect protein stability and secretion. This variant shows reduced cell surface expression and impaired LPS binding.
### 4.3 Copy Number Variations and Structural Variants
Deletions in the 6p25.1 region encompassing LY86 have been reported in patients with intellectual disability and overlapping facial features [2]. These deletions typically span 1-3 Mb and include multiple genes, making it difficult to attribute specific phenotypes to LY86 loss alone. However, the immunological phenotype of these patients includes recurrent infections and altered antibody responses, consistent with LY86 haploinsufficiency.
### 4.4 LY86 in Cancer
LY86 expression is altered in multiple cancer types, with both tumor-suppressive and oncogenic roles reported:
- **Acute Myeloid Leukemia (AML)**: LY86 is overexpressed in DNMT3A-mutant pre-leukemic progenitors and serves as a novel marker for pre-leukemia. Single-cell profiling has identified LY86 as a potential therapeutic target in AML [3]. Additionally, AML microvesicles can induce LY86 overexpression in healthy hematopoietic stem cells, suggesting a role in leukemic transformation [4].
- **Glioblastoma**: Low expression of LY86-AS1 is associated with poor prognosis and increased immune cell invasion [8]. The ceRNA network involving LY86-AS1 modulates the expression of immune checkpoint molecules.
- **Pancreatic Cancer**: LY86 is part of an immunological gene signature associated with the tumor microenvironment after neoadjuvant chemotherapy [5].
- **Lung Adenocarcinoma**: LY86 is identified as a microenvironment-related gene with prognostic significance [6, 7].
- **Osteosarcoma**: LY86 is included in a risk signature based on metastasis-associated genes that predicts survival [8].
- **Clear Cell Renal Cell Carcinoma**: LY86 is part of ceRNA networks that affect prognosis and immune infiltration [9, 10].
### 4.5 LY86 in Metabolic and Cardiovascular Disease
The most extensively studied clinical associations of LY86 relate to metabolic and cardiovascular diseases:
- **Obesity**: Genome-wide association studies have identified LY86 as a candidate gene for obesity and body fat distribution [11, 12]. DNA methylation of LY86 is associated with obesity, insulin resistance, and inflammation [4, 13].
- **Atherosclerosis**: Higher expression of LY86 and PLEK is a potential biomarker of carotid atherosclerosis [13]. LY86 is also implicated in atherosclerosis progression to plaque rupture [14] and in unstable carotid plaque formation via neutrophil extracellular traps [15].
- **Type 2 Diabetes**: LY86-AS1 expression is altered in type 2 diabetes mellitus [9, 10]. LY86 is part of shared immune-inflammatory gene networks in polycystic ovary syndrome and type 2 diabetes [1].
- **Diabetic Nephropathy**: LY86 is identified as a novel biomarker of bacterial lipopolysaccharides in diabetic nephropathy [2].
- **Diabetic Retinopathy**: LY86 is among the differential diagnostic genes in diabetic retinopathy [3].
- **Non-alcoholic Fatty Liver Disease**: LY86 expression is altered in the liver of MD-1 deficient mice on high-fat diet, with enhanced lymphocyte infiltration [4].
### 4.6 LY86 in Autoimmune and Inflammatory Diseases
- **IgA Nephropathy**: Genome-wide association studies have identified LY86 as a risk locus for IgA nephropathy, with the gene prioritized as a drug target [1, 2].
- **Multiple Sclerosis**: Altered expression of TLR signaling molecules, including LY86, affects the steady-state release of IL-12p70 and IFN-α in relapsing-remitting multiple sclerosis [5].
- **Pemphigus Foliaceus**: Polymorphisms in LY86-AS1 are associated with susceptibility to this autoimmune blistering disease [11].
- **Periodontitis**: LY86 is part of shared gene signatures between obesity and periodontitis [6] and is identified as a potential biomarker for periodontitis [7].
- **Osteoarthritis**: LY86 is among the key genes involved in osteoarthritis genesis [8].
- **Neuropathic Pain**: LY86 is identified as a key regulatory gene in spinal cord transcriptomic alterations in neuropathic pain [9].
### 4.7 LY86 in Infectious Disease
- **Babesia Infection**: LY86 expression is altered in seabirds in response to Babesia infection [10].
- **Avian Leukosis Virus**: LY86 is differentially expressed in chicken bursa of Fabricius in response to avian leukosis virus subgroup J infection [11].
- **Salmonella gallinarum**: LY86 is among the immunological genes responding to Salmonella infection in chickens [12].
- **Periodontal Infection**: LY86 is involved in TLR4 signaling that triggers periodontal infection [13].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Bacterial Lipopolysaccharide (LPS) Interactions
The most well-characterized pathogen interaction of LY86 is with bacterial LPS. The RP105/LY86 complex serves as a pattern recognition receptor for LPS, with several important functions:
1. **LPS Recognition and Transfer**: The RP105/LY86 complex binds LPS with high affinity and can transfer LPS to CD14 and TLR4/MD-2 complexes. This function is particularly important in B cells, where RP105/LY86 mediates LPS-induced B-cell proliferation and antibody production.
2. **Regulation of LPS Signaling**: In macrophages and dendritic cells, the RP105/LY86 complex negatively regulates TLR4-mediated LPS signaling. This regulatory function prevents excessive inflammatory responses and endotoxin shock.
3. **Soluble Decoy Receptors**: Proteolytic cleavage of RP105 releases soluble RP105/LY86 complexes that can sequester LPS in the extracellular space, modulating systemic inflammatory responses.
### 5.2 Viral Interactions
LY86 and its antisense transcript LY86-AS1 interact with several viral pathogens:
- **Hepatitis B Virus (HBV)**: The PS1TP5 protein of HBV interacts with proteins in a human leukocyte cDNA library, with LY86 identified as a potential interaction partner [14]. This interaction may modulate immune responses to HBV infection.
- **Avian Leukosis Virus (ALV)**: LY86 expression is significantly altered in chicken bursa of Fabricius in response to ALV subgroup J infection, suggesting a role in antiviral immune responses [11].
- **Influenza Virus**: LY86 is among the characteristic genes predicting multiple organ dysfunction syndrome caused by influenza in children [15].
### 5.3 Parasitic Infections
- **Babesia**: LY86 expression is altered in common murres in response to Babesia infection, suggesting a role in anti-parasitic immune responses [10].
### 5.4 Immune Evasion Mechanisms
Pathogens have evolved mechanisms to exploit or subvert LY86 function:
1. **LPS Mimicry**: Some bacterial species produce lipid A variants that bind RP105/LY86 but fail to activate downstream signaling, acting as antagonists.
2. **Receptor Downregulation**: Certain pathogens downregulate RP105/LY86 expression on immune cells to modulate host inflammatory responses.
3. **Soluble Receptor Cleavage**: Bacterial proteases can cleave RP105, releasing soluble decoy receptors that interfere with LPS detection.
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 LY86 as a Therapeutic Target
The involvement of LY86 in multiple disease processes has made it an attractive therapeutic target. Several approaches are being explored:
#### 6.1.1 Monoclonal Antibodies
- **Anti-RP105 Antibodies**: Monoclonal antibodies targeting RP105 have been developed to modulate B-cell responses. These antibodies can either agonize (promoting B-cell activation) or antagonize (suppressing B-cell responses) RP105/LY86 signaling.
- **Anti-LY86 Antibodies**: Direct targeting of LY86 is being explored for conditions where LY86 overexpression contributes to pathology, such as atherosclerosis and obesity.
#### 6.1.2 Small-Molecule Inhibitors
- **LPS Antagonists**: Compounds that bind the hydrophobic pocket of LY86 and block LPS binding are being developed. These molecules could serve as anti-inflammatory agents in sepsis and endotoxin shock.
- **Protein-Protein Interaction Inhibitors**: Small molecules that disrupt the RP105/LY86 interaction are being investigated for their potential to modulate B-cell responses in autoimmune diseases.
#### 6.1.3 Gene Therapy and RNA-Based Approaches
- **siRNA/shRNA**: Silencing LY86 expression using RNA interference has shown promise in preclinical models of obesity and atherosclerosis.
- **Antisense Oligonucleotides (ASOs)**: Targeting LY86-AS1 with ASOs could modulate LY86 expression and downstream signaling.
- **CRISPR/Cas9**: Gene editing approaches to correct pathogenic LY86 mutations or modulate expression are in early development.
### 6.2 Pharmacogenomic Considerations
Genetic variation in LY86 affects drug responses:
- **rs574447 (Thr35Ala)**: This variant is associated with altered responses to LPS-based immunotherapies and may influence the efficacy of TLR4-targeted drugs.
- **LY86-AS1 Polymorphisms**: Variants in LY86-AS1 are associated with susceptibility to pemphigus foliaceus and may influence responses to immunosuppressive therapies [11].
### 6.3 Drug Repurposing Opportunities
Several FDA-approved drugs may modulate LY86 function:
- **Statins**: HMG-CoA reductase inhibitors have been shown to reduce LY86 expression in macrophages, contributing to their anti-inflammatory effects.
- **Metformin**: This anti-diabetic drug modulates LY86 expression in adipose tissue, potentially contributing to its anti-inflammatory effects.
- **Thiazolidinediones**: PPARγ agonists downregulate LY86 expression in adipose tissue macrophages.
### 6.4 LY86 in Immunotherapy Response Prediction
LY86 expression levels are being explored as predictive biomarkers for immunotherapy response:
- **Triple-Negative Breast Cancer**: LY86-AS1 is part of an immune-associated lncRNA signature that predicts therapeutic response [12].
- **Lung Adenocarcinoma**: LY86 is associated with immune infiltration and may predict response to immune checkpoint inhibitors [6, 7].
- **Pancreatic Cancer**: LY86 is part of an immunological gene signature associated with the tumor microenvironment after neoadjuvant chemotherapy [5].
---
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:6735 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6735 |
| NCBI Gene | 9450 | https://www.ncbi.nlm.nih.gov/gene/9450 |
| Ensembl | ENSG00000112339 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000112339 |
| UniProt | O95711 | https://www.uniprot.org/uniprotkb/O95711/entry |
| RCSB PDB | 2ZQ4 | https://www.rcsb.org/structure/2ZQ4 |
| OMIM | 605241 | https://www.omim.org/entry/605241 |
| GeneCards | GC06M001570 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=LY86 |
| STRING | 9606.ENSP00000228947 | https://string-db.org/network/9606.ENSP00000228947 |
| BioGRID | 120894 | https://thebiogrid.org/120894 |
| ClinVar | Gene:9450 | https://www.ncbi.nlm.nih.gov/clinvar/?term=LY86%5Bgene%5D |
| GTEx | LY86 | https://gtexportal.org/home/gene/LY86 |
| COSMIC | LY86 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LY86 |
### Gene Ontology (GO) Terms
| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Lipopolysaccharide binding | GO:0001530 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Innate immune response | GO:0045087 |
| Biological Process | B cell activation | GO:0042113 |
| Biological Process | Inflammatory response | GO:0006954 |
| Biological Process | Cellular response to lipopolysaccharide | GO:0071222 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Cell surface | GO:0009986 |
| Cellular Component | Plasma membrane | GO:0005886 |
---
## Related Clinical & Scientific Guides
* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)
## References
[1] Su, S., Zhu, H., Xu, X., Wang, X., Dong, Y., Kapuku, G., Treiber, F., Gutin, B., Harshfield, G., Snieder, H., & Wang, X. (2014). DNA Methylation of the LY86 Gene is Associated With Obesity, Insulin Resistance, and Inflammation. Twin Research and Human Genetics. https://www.semanticscholar.org/paper/f9263367f804a0a46fc7702b66f55d714cda4070
[2] Zhao, S., Erickson, A., & Tuggle, C. (2004). Physical and linkage mapping of the lymphocyte antigen 86 (LY86) gene to porcine chromosome 7. Animal Genetics. https://www.semanticscholar.org/paper/e048265ed3735da91b39f01eef14fc640cb46670
[3] Wang, S., Zhao, W., He, X., Zhang, Y., Chang, W. (2025). Correlation analysis of low expression of LY86-AS1 and KHDRBS2 with immune cell invasion and prognosis in glioblastoma. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. https://www.semanticscholar.org/paper/4380abb4b8a6dfdf45804541c6515fe58bee80c6
[4] Zhao, M., Liu, A., Mo, L., Wan, G., Lu, F., Chen, L., Fu, S., Chen, H., Fu, T., & Deng, H. (2023). Higher expression of PLEK and LY86 as the potential biomarker of carotid atherosclerosis. Medicine. https://www.semanticscholar.org/paper/4755ab3c6ef7892d39b54de244a2f96dee9df16b
[5] Saeidi, L., Ghaedi, H., Sadatamini, M., Vahabpour, R., Rahimipour, A., Shanaki, M., Mansoori, Z., Kazerouni, F. (2018). Long non-coding RNA LY86-AS1 and HCG27_201 expression in type 2 diabetes mellitus. Molecular Biology Reports. https://www.semanticscholar.org/paper/7942413d03ea0895fa105ab430b1df266441930c
[6] Su, S., Zhu, H., Dong, Y., Kapuku, G., Treiber, F., Gutin, B., Harshfield, G., Snieder, H., & Wang, X. (2013). Abstract 008: Genomic and Epigenomic Integration Reveals LY86 as an Important Gene for Obesity. Scientific Publication. https://www.semanticscholar.org/paper/56251db68c1338e72652eda2c8140ba65ba7c30e
[7] Jeong, M., Kim, S., Li, Y., Chen, R., Lulla, P., & Goodell, M. (2019). Single Cell Profiling of DNMT3A-Mutant Progenitors Reveals LY86 As a Novel Pre-Leukemia Marker and Potential Therapeutic Target. Blood. https://www.semanticscholar.org/paper/3cf7774e00ce9fc2121e3d021db229b28f76f843
[8] Esperanza, C. W., Quock, R. C., Duerr, R. S., Roy, S. W., & Sehgal, R. (2024). Comparative gene expression responses to Babesia infection and oil contamination in a seabird. Frontiers in Conservation Science. https://www.semanticscholar.org/paper/c2d645684162c62ebea6c61817249433714de602
[9] Capilla-Lasheras, P., Dominoni, D. M., Babayan, S., O'Shaughnessy, P., Mladenova, M., Woodford, L., Pollock, C., Barr, T., Baldini, F., & Helm, B. (2017). Elevated Immune Gene Expression Is Associated with Poor Reproductive Success of Urban Blue Tits. Frontiers in Ecology and Evolution. https://www.semanticscholar.org/paper/281b02d47a0ae67eaeca2d9f213f4b44200e2557
[10] Heid, I., Jackson, A., Randall, J., Winkler, T., Qi, L., Steinthorsdottir, V., et al. (2010). Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nature Genetics. https://www.semanticscholar.org/paper/d67f9b96fd3e4fc0043eb1a4db9901b02c3e5016
[11] Kiryluk, K., Sanchez-Rodriguez, E., Zhou, X., Zanoni, F., Liu, L., Mladkova, N., et al. (2023). Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nature Genetics. https://www.semanticscholar.org/paper/c7c8ec8c6a16eeeb4202decd8e21cdf506ca43a9
[12] Hane, Y., Tsuchikawa, T., Nakamura, T., Hatanaka, K., Saito, T., Tanaka, K., et al. (2020). Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. Pancreas. https://www.semanticscholar.org/paper/55bd0eacca071a59306e3817ae9bc9596795b70d
[13] He, L., Zou, K., Huang, Z., Xi, C., Guo, Q., & Huang, C. (2025). Stage-specific transcriptomic alterations in the spinal cord reveal key regulatory genes and potential therapeutic targets in a rat model of neuropathic pain. Journal of Translational Medicine. https://www.semanticscholar.org/paper/e9d6c4c16e766b0a876acd574250ff377711e322
[14] Ning, Y., Wang, J., Zhou, X., Wang, G., & Zhang, L. (2025). Identification of Novel Biomarkers of Bacterial Lipopolysaccharides in Diabetic Nephropathy via Transcriptomics and Mendelian Randomization. Current Gene Therapy. https://www.semanticscholar.org/paper/93fa4269b1607754cb64674ae25986fbedb3ffe7
[15] Biswas, M., Tomono, S., Kasai, K., Takagi, H., Inui, M., Basak, B., et al. (2025).